Relevant Research Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomised controlled trials Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials Retatrutidea game changer in obesity pharmacotherapy Unleashing the power of retatrutide: a possible triumph over obesity Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomised phase 2a trial Retatrutide in type 2 diabetes mellitus and obesity: an overview
17, e221e227 10.1016/j.ijid.2012.11.019 [DOI] [PubMed] [Google Scholar] 94.Dhir S., Tarasenko M., Napoli E
Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia
Participants with renal impairment were excluded if they had previously undergone renal transplantation or had unstable renal function or acute exacerbation of renal disease within 14 days of baseline, as indicated by recent history or worsening of clinical or laboratory signs
For instance, dietary polyphenols such as caffeic acid and quercetin react slowly, which may lead to underestimation when using short reaction times (Pulido et al
